Ipamorelin
- Evidence
- Limited research
- Class
- GHRP / ghrelin receptor agonist
Ipamorelin belongs to the GHRP / ghrelin receptor agonist class. This library groups it under bones & muscles. Its source category is Not FDA-approved.
At a glance
| Compound class | GHRP / ghrelin receptor agonist |
|---|---|
| Body system | Bones & muscles |
| Use or research focus | Recovery, body composition, sleep |
| Regulatory status | Not FDA-approved; removed from 503A Category 2 (Apr 2026); status unsettled |
| Source evidence rating | Limited research |
How does Ipamorelin work?
Selective GH release with minimal cortisol/prolactin.
The source catalog maps this mechanism to Pituitary, Muscle. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
For an unapproved use or compound, safety and effectiveness may be uncertain. Products sold for research are not a substitute for prescribed care. Do not infer a human dose, injection protocol, or treatment recommendation from preclinical research.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is Ipamorelin?
Ipamorelin belongs to the GHRP / ghrelin receptor agonist class. This library groups it under bones & muscles. Its source category is Not FDA-approved. Its recorded use or research focus is: Recovery, body composition, sleep.
Is Ipamorelin FDA-approved?
The catalog records: Not FDA-approved; removed from 503A Category 2 (Apr 2026); status unsettled. Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Where can I read the research?
The Citations tab contains 12 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for bones & muscles
Factual catalog fields and citation links are adapted from Superpower’s Ipamorelin guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with Ipamorelin in the source dataset. Open a source to review its study design, population, limitations, and date.
- 01ghrelinmy.clevelandclinic.org
- 02released GH without raising ACTH or cortisolpubmed.ncbi.nlm.nih.gov
- 03studydoi.org
- 04a terminal half-life of 2 hourspubmed.ncbi.nlm.nih.gov
- 05studydoi.org
- 06modeldoi.org
- 07114 patients analyzedpubmed.ncbi.nlm.nih.gov
- 08bulk drug substances nominated but withdrawnfda.gov
- 09only blunted their effect but nearly abolished GHRH'spubmed.ncbi.nlm.nih.gov
- 10also raised prolactin, ACTH, and cortisolpubmed.ncbi.nlm.nih.gov
- 11Category 3 for 503A compoundingfda.gov
- 12Detection methodology in urine has been validatedpubmed.ncbi.nlm.nih.gov